Female patients of childbearing potential are not eligible unless a negative pregnancy test result has been obtained
Female subjects of childbearing potential must have a negative serum pregnancy within three days prior to registration for protocol therapy
Female patients of childbearing potential are not eligible unless a negative pregnancy test result has been obtained
Patients who are pregnant; (a negative pregnancy test is required for female patients of childbearing potential)
Female patients of childbearing potential are not eligible unless a negative pregnancy test result has been obtained
Female patients of childbearing potential must have a negative serum or urine pregnancy test
Female patients of childbearing potential must have a negative serum pregnancy test within 7 days prior to enrollment
Female subjects of childbearing potential must have a negative serum or urine pregnancy test within 8 days of initiating protocol therapy
Female patients who are pregnant or currently breastfeeding; female patients of childbearing potential must have a negative serum pregnancy test prior to enrollment
Female subjects of childbearing potential must have a negative serum or urine pregnancy test within 8 days of initiating protocol therapy
If female of childbearing potential, must have a negative pregnancy test within 7 days of initiating treatment. Childbearing potential is defined by: those who have not been surgically sterilized and/or have had a menstrual period in the past year.
Female subjects of childbearing potential must have a negative serum pregnancy test at screening
Female subjects of childbearing potential must have a negative pregnancy test at screening
Female subjects of childbearing potential must have a negative serum pregnancy test at screening
Female patients must have a negative serum pregnancy test or be of non-childbearing potential.
Negative serum pregnancy test within 7 days prior to the administration of the study drugs for female patients of childbearing potential.
Pregnancy (negative serum pregnancy test to be obtained within 6 days prior to enrollment for subjects of childbearing potential)
Female participants of childbearing potential are to have a negative serum pregnancy test
Female patients of childbearing potential must have a negative pregnancy test within 1 week prior to beginning study treatment.
Female patients of childbearing potential must have a negative serum pregnancy test at the time of enrollment
Has a negative serum pregnancy test within 7 days of first dose of study treatment (female patients of childbearing potential)
Female patients of childbearing potential must have a negative pregnancy test, as measured by serum or urine testing
Female subjects of childbearing potential must be nonpregnant, nonlactating, and have a negative pregnancy test result at Screening and Day 1 of Cycles 1-6.
Within 7 days of enrollment and with 24 h of starting lymphodepleting chemotherapy: Negative serum pregnancy test (female subjects of childbearing potential).
For female subjects of childbearing potential, a negative serum pregnancy test.
For female subjects of childbearing potential, a negative urine or serum pregnancy test prior to the start of study therapy.
Female patients of childbearing potential must have a negative serum pregnancy test within 14 days prior to enrollment; male and female patients must use an effective contraceptive method during the study and for a minimum of 6 months after study treatment
Female participants of childbearing potential must have negative results for pregnancy test performed:
Female subject of childbearing potential should have a negative pregnancy test within 14 days prior to receiving the first dose of study medication
Female subjects of childbearing age must have a negative serum pregnancy test at study entry
Female patients of childbearing potential must have a negative serum pregnancy test within 7 days prior to enrollment
Female patients of childbearing potential must have a negative urine or serum pregnancy test confirmed prior to enrollment
Patients of childbearing potential must have a negative pregnancy test within 7 days prior to treatment start to be eligible
Negative pregnancy test within 14 days of day 1 cycle 1 for female patients of childbearing potential.
Female patients of childbearing potential, negative urine pregnancy test done =< 7 days prior to study registration
Female subjects of childbearing potential should have a negative serum pregnancy =< 7 days prior to registration
Female patients of childbearing potential must have a negative pregnancy test < 1 week prior to enrollment.
Female patient of childbearing potential has a negative serum pregnancy test within 7 days of study enrollment
Female patients of childbearing potential must have a negative serum pregnancy test within 7 days
Have a negative pregnancy test if a female with childbearing potential
Female patients of childbearing potential must have a negative serum pregnancy test confirmed within 7 days prior to enrollment
Female patients of childbearing potential must have a negative urine or serum pregnancy test confirmed prior to enrollment
Negative pregnancy test (urine or serum) for female patients of childbearing potential
Negative pregnancy test in female patients if applicable (childbearing potential who have received a reduced intensity conditioning regimen).
Female patients of childbearing potential must have a negative pregnancy test within 14 days of radiation start
Negative pregnancy test in female patients of childbearing potential
Negative pregnancy test in female patients of childbearing potential
STEP 2: Negative pregnancy test in female patients of childbearing potential
Female patients of childbearing potential must have a negative pregnancy test within 2 weeks prior to entering this study
Negative pregnancy test in female patients if applicable (childbearing potential who have received a reduced intensity conditioning regimen)
Female patients of childbearing potential must have a negative pregnancy test within 7 days of the start of treatment.
Female patients of childbearing potential must have a negative serum or urine pregnancy test
Negative pregnancy test of the blood within 7 days of starting treatment in female patient of childbearing potential
A negative pregnancy test (if female of childbearing potential).
Female patients of childbearing potential are not eligible unless a negative pregnancy test result has been obtained
Female patients of childbearing potential must have a negative serum pregnancy test within 2 weeks prior to enrollment
Female patients of childbearing potential must have a negative pregnancy test within 2 weeks prior to enrollment, and
Female patients of childbearing potential must have a negative serum or urine pregnancy test
Female participants of childbearing potential must have a negative serum pregnancy test within the 7 days prior to the first study drug administration.
A negative serum pregnancy test, if female of reproductive potential
Female patients of childbearing potential are not eligible unless a negative pregnancy test result has been obtained
Female patients of childbearing potential are not eligible unless a negative pregnancy test result has been obtained
Female patients of childbearing potential are not eligible unless a negative pregnancy test result has been obtained
Female patients of childbearing potential must have negative serum pregnancy test within 14 days of starting protocol therapy
Female patients of childbearing potential must have a negative pregnancy test
Female patients of childbearing potential must have a negative serum pregnancy test within 7 days of study entry
If female of childbearing potential, serum pregnancy test is negative
For female patients of childbearing potential, have a negative pregnancy test documented prior to randomization.
Negative serum pregnancy test if female and of childbearing potential
Any patients of childbearing potential must have a negative pregnancy test
Female participants of childbearing potential must have a negative serum pregnancy test within 7 days prior to first dose.
Female patients of childbearing potential must have negative urine pregnancy test no more than 3 days prior to starting study treatment
Female participants must have a negative pregnancy test at screening if of childbearing potential or be of non-childbearing potential
Subject is of childbearing potential and does not have a negative pregnancy test.
Female patients of childbearing potential are not eligible unless a negative pregnancy test result has been obtained
Female patients of childbearing potential are not eligible unless a negative pregnancy text result has been obtained
Within 14 days of enrollment: If female of childbearing potential, urine pregnancy test is negative
Female subject of childbearing potential should have a negative pregnancy test or documentation of absence of pregnancy by a gynecologist within 2 weeks of initiating radiation therapy
For female subjects with reproductive potential: a negative serum pregnancy test
Female patient of childbearing potential has a negative serum or urine pregnancy test within 14 days prior to administration of study therapy
Female subject of childbearing potential should have a negative serum pregnancy within 2 weeks prior to starting radiation therapy or undergoing ablation
Female subject of childbearing potential should have a negative serum pregnancy test
Female patients of childbearing age must have negative pregnancy test
Female patients of childbearing potential must have a negative pregnancy test within 14 days of radiation start
For female participants of childbearing potential, a negative pregnancy test must be documented prior to enrollment.
If female of childbearing potential, negative pregnancy test
If a female of childbearing potential, had a negative serum pregnancy test within 14 days before enrollment, or within 72 hours before enrollment where required
Female patients of childbearing potential must have negative serum pregnancy test =< 21 days prior to starting study treatment
Female patients of childbearing potential must have a negative serum pregnancy test within 2 weeks prior to enrollment
Female patients of childbearing potential must have a negative pregnancy test at screening
Negative serum pregnancy test within 7 days prior to enrollment in female subjects with reproductive potential
If female of childbearing potential, pregnancy test is negative
Female subjects of childbearing potential, as defined in parent study, must have negative serum pregnancy tests at the time of transition to this study.
Patients of childbearing age must have a negative pregnancy test
Female patients of childbearing potential must have a negative serum pregnancy test within 3 days prior to enrollment
Female subjects of childbearing potential, as defined in parent study, must have negative serum pregnancy tests at the time of transition to this study.
Female patient who is of childbearing potential must have a negative serum pregnancy test result within 3 weeks prior to starting study drugs.
Female subject of childbearing potential should have a negative serum pregnancy within 28 days prior to receiving the first dose of study medication
Female patients of childbearing potential must have a negative pregnancy test within 2 weeks prior to enrollment
Female patients of childbearing potential must have a negative serum or urine pregnancy test, whichever is considered standard by the institution
Female patients of childbearing potential must have a negative urine or serum pregnancy test confirmed prior to enrollment.
Female patients of childbearing potential must have a negative urine or serum pregnancy test confirmed within 2 weeks prior to enrollment.
If female of childbearing potential, participant presents with a negative blood pregnancy test
Female patients cannot be of childbearing age, or if they are, must have a negative pregnancy test prior to enrollment and be willing to use contraceptives during treatment and continue for 6 additional months
Female patient of childbearing potential has a negative pregnancy test within 14 days prior to the start of study drug.
Female patients who are not of childbearing potential, and female patients of childbearing potential who agree to use adequate contraceptive measures, who are not breastfeeding, and who have a negative serum pregnancy test within 72 hours prior to start of treatment.
Female patients of childbearing potential must have a negative serum or urine pregnancy test at the time of enrollment
RECURRENT/ PROGRESSIVE DIPG (STRATUM 1): Female patients of childbearing potential must have a negative serum or urine pregnancy test
NON-PROGRESSED DIPG (STRATUM 2): Female patients of childbearing potential must have a negative serum or urine pregnancy test
Female patients of childbearing potential are not eligible unless a negative pregnancy test result has been obtained
Negative pregnancy test in female patients if applicable (childbearing potential who have received a reduced intensity conditioning regimen).
Female patients of childbearing potential must have a negative urine or serum pregnancy test confirmed prior to enrollment.
Female subjects of childbearing age must have a negative serum pregnancy test at study entry
Female patients of childbearing potential must be non-pregnant, non-lactating, and have a negative pregnancy test result prior to enrollment in the study;
If female and of childbearing potential, documentation of negative pregnancy test (serum or urine) within 7 days prior to first dose
If the subject is a female of childbearing potential, has she had a negative serum pregnancy test within the past 21 days?
Female patients of childbearing potential must have a negative serum or urine pregnancy test result at time of pre-treatment screening.
Female patients of childbearing potential must have a negative serum pregnancy test
Female patient of childbearing potential has a negative pregnancy test within 14 days prior to the start of study drug
If female and of childbearing potential, documentation of negative pregnancy test prior to enrollment.
Female participants of childbearing potential must have a negative serum pregnancy test
Female subject of childbearing potential must have a negative pregnancy test at screening
Female participants of childbearing potential must have a negative pregnancy test (urinary or serum beta-HCG).
Female patients of childbearing age must have a negative pregnancy test
Female patients of childbearing potential are not eligible unless a negative pregnancy test result has been obtained
Female subjects of childbearing potential must have a negative plasma pregnancy test upon study entry
Urine or serum pregnancy test: negative for female patients of childbearing potential
Negative pregnancy test in female patients if applicable (childbearing potential who have received a reduced intensity conditioning regimen)
Pregnancy; female participants of childbearing potential must have documented negative urine or serum pregnancy test result not older than 7 days; male patients with reproductive potential will be counseled not to procreate during the study
Female patients who are pregnant are not eligible; women of childbearing potential require a negative pregnancy test prior to starting study drug
Female patients who are pregnant are not eligible; women of childbearing potential require a negative pregnancy test
Female patients of childbearing potential must have a negative pregnancy test at screening
Female subjects of childbearing potential must have a negative pregnancy test
Female patients who are pregnant are not eligible; women of childbearing potential require a negative pregnancy test prior to enrollment
A negative serum pregnancy test at baseline, but within 21 days of randomization, for persons of childbearing potential only
Negative serum or urine pregnancy test for female patients of childbearing age and potential (as defined by MSKCC Standards & Guidelines), from assays obtained < 2 weeks prior to study enrollment
Negative pregnancy test, to be performed on female patients of childbearing potential within 1 week before administration of radioactive material
Negative serum pregnancy test for female patients of childbearing age and potential (as defined by MSKCC standards & guidelines), from assays obtained < 2 weeks prior to study enrollment; patients will be advised against having unprotected sexual intercourse from the time of the negative serum pregnancy test until after completing their participation in the study
Negative serum pregnancy test (female of childbearing potential only)
Female patients of childbearing potential must have a negative serum or urine pregnancy test within 7 days of enrollment
Female subjects of childbearing potential (unless they have a negative serum or urine pregnancy test within 3 days prior to start of study treatment)
if female of childbearing potential must have a negative pregnancy test within 24 hours of enrollment
If female of childbearing potential, pregnancy test is negative; (in these instances, the patient will need to provide documentation of negative pregnancy test results)
Female subjects of childbearing potential must have a negative serum pregnancy test within 7 days prior to infusion
Criteria 9, Female subjects of childbearing potential should have a negative serum pregnancy test within 1 week prior to enrollment
Female subject of childbearing potential must have a negative pregnancy test within 72 hours prior to enrollment.
Female patients of childbearing potential must have a negative pregnancy test within 1 week prior to beginning study treatment.